Abstract Volume:4 Issue-12 Year-2016 Original Research Articles
|Online ISSN : 2347 - 3215
Issues : 12 per year
Publisher : Excellent Publishers
Email : email@example.com
Multi drug resistant (MDR) tuberculosis (TB) has become more prevalent in recent years and second line drugs are not as effective as the standard therapy and are more toxic and expensive. There is an urgent need for new antitubercular drugs. The components of the cell envelope of Mycobacteria have been the subject of intense research for a number of years because of the fact that enzymes involved in their biosynthetic pathways including mycolic acids, offer attractive and selective targets for the developments of novel antimycobacterial agents. The mechanisms of action of various mycolic acid inhibitors like Isoniazide ( INH) and Ethionamide (ETH) have been studied intensively. Recently, mycolic acid inhibitors like Thiolactomycin (TLM), Triclosan (TRC) and Isoxyl (ISO) have been reported to have potent activity against MDR strains of M. tuberculosis. Present study was conducted with the objective of determining the efficacy of ISO in vitro against M. tuberculosis strains in comparison to other mycolic acid inhibitors. Minimum Inhibitory Concentration pattern of clinical isolates of M. tuberculosis to mycolic acid synthesis inhibitors namely TRC, TLM, ISO, INH And ETH were determined by agar dilution method.. Total 10 MDR strains and 10 susceptible strains of Mycobacterum tuberculosis (M. tuberculosis) along with standard strain of M. tuberculosis H37Rv were included in the study. This study shows promising activity of ISO against various strains of M.tuberculosis in comparison to other mycolic acid inhibitors. Hence more study on this compound will be beneficial in drug development process.
How to cite this article:Shashikant Vaidya, Shreyasi Mulye, Mohan Kulkarni, Geeta Koppikar, Abhay Chowdhary. 2016. Determination of the Efficacy of Isoxyl, A Mycolic Acid Inhibitor in Vitro against M. tuberculosis Strains in Comparison to Other Mycolic Acid Inhibitors.Int.J.Curr.Res.Aca.Rev. 4(12): 103-117